Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAdalta Ltd

Adalta Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.002 AUD 0.00(0%)
Last update at 2026-11-11T23:30:00Z
VOLUME
332396
Market Cap
6.42M

Momentum Score

…

AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

AdAlta Ltd is an Australian clinical-stage biotechnology company developing protein therapeutics using a proprietary i-body platform focused on fibrotic and inflammatory diseases. Long-term growth drivers include clinical progress, platform extension into new indications and partnering/licensing opportunities, and investors may find potential in platform scalability and clinical validation pathways.
Principal risks include clinical development and regulatory failure, limited revenues and recurring financing needs that may cause dilution, and competition from larger biotech and pharmaceutical companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.40M
Revenue Per Share
-
Gross Profit TTM
0.13M
Debt / Equity
0.80
ROE
-62871.64%
Net Debt
-1.28M
ROCE
-1296.92%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -5.09M -4.50M -7.12M -4.85M -6.06M
Net income -4.68M -4.50M -5.38M -4.85M -6.06M
Selling general administrative 1.19M 2.56M 2.40M 1.73M 4.33M
Selling and marketing expenses - 0.08M 0.21M 2.46M -
Gross profit - 0.46M 1.51M 2.99M 0.99M
Reconciled depreciation - 0.09M 0.06M 0.03M 0.03M
Ebit - -4.46M -5.32M -4.87M -5.95M
Ebitda -4.80M -4.45M -5.26M -4.84M -5.92M
Depreciation and amortization - 0.01M 0.06M 0.03M 0.03M
Operating income -4.80M -4.38M -5.26M -4.87M -7.76M
Other operating expenses 4.80M 5.05M 7.00M 7.31M 8.75M
Interest expense 0.29M 0.06M 0.12M 0.06M 0.11M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.07M 0.02M 0.05M 0.04M 0.00M
Net interest income -0.22M -0.04M -0.07M -0.06M -0.11M
Income tax expense -0.40M - -1.74M - 0.11M
Total revenue - 0.68M 1.74M 3.47M 2.76M
Total operating expenses 4.80M 4.83M 6.77M 7.78M 8.75M
Cost of revenue - 0.22M 0.23M 0.47M -
Total other income expense net -0.29M -0.13M -1.86M 0.02M 1.70M
Net income from continuing ops -4.68M -4.50M -5.38M -4.85M -6.06M
Net income applicable to common shares - -4.50M -5.38M -4.85M -6.06M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 1.72M 2.14M 5.57M 7.73M 10.65M
Other current assets 0.16M - 0.34M 0.21M 0.08M
Total liab 1.35M 2.74M 3.54M 5.82M 5.27M
Total stockholder equity 0.37M -0.60M 2.03M 1.91M 5.38M
Other current liab 1.04M - 0.60M 0.67M 0.69M
Common stock 54.63M - 47.40M 42.18M 41.01M
Capital stock 54.63M 49.20M - 42.18M 41.01M
Retained earnings -56.71M -52.02M -47.52M -42.14M -37.29M
Other liab - - - 0.01M 0.02M
Other assets - - 0.00M - -
Cash 1.28M 1.31M 3.13M 4.96M 8.74M
Total current liabilities 1.35M 1.34M 2.22M 5.81M 3.63M
Net debt -1.28M 0.46M -1.52M -0.95M -4.74M
Short term debt - - 1.52M 4.01M 2.39M
Short long term debt - 0.45M - 4.01M 2.39M
Short long term debt total - - 1.62M 4.01M 4.00M
Other stockholder equity - - - 1.87M 1.66M
Property plant equipment - - - 0.04M 0.06M
Total current assets 1.72M 2.14M 5.29M 7.70M 10.58M
Net tangible assets - - - 1.91M 5.38M
Net receivables 0.27M - 1.82M 2.70M 1.79M
Long term debt - 1.32M - 0.00M 1.61M
Inventory - - - - -0.02M
Accounts payable 0.31M 0.64M 0.09M 1.12M 0.56M
Accumulated other comprehensive income 2.45M - 2.15M 1.87M 1.66M
Non currrent assets other - - -0.00M - -
Non current assets total 0.00M 0.00M 0.28M 0.04M 0.06M
Long term debt total - - - 0.00M 1.61M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 0.11M -0.06M -0.00M -0.03M
Change to liabilities - - - 0.45M 0.23M
Total cashflows from investing activities - 0.11M -0.06M -0.00M -0.03M
Net borrowings -0.42M -0.10M -1.40M - 2.28M
Total cash from financing activities 4.42M 1.00M 3.67M 1.27M 7.02M
Change to operating activities - - - -0.13M 0.00M
Net income -4.68M -4.50M -5.38M -4.85M -6.17M
Change in cash -0.02M -1.83M -1.66M -3.87M 2.87M
Begin period cash flow 1.31M 3.13M 4.79M 8.66M 5.79M
End period cash flow 1.28M 1.31M 3.13M 4.79M 8.66M
Total cash from operating activities -4.44M -2.94M -5.26M -5.13M -6.14M
Issuance of capital stock 5.33M 1.28M 5.41M 1.28M 5.00M
Depreciation - - 0.06M 0.03M 0.03M
Other cashflows from investing activities - 0.11M - - -
Change to account receivables 0.40M 1.12M 0.74M -0.91M 1.32M
Sale purchase of stock -0.08M -0.19M -0.29M -0.07M -0.27M
Other cashflows from financing activities 0.41M -0.19M -0.06M 0.06M 4.00M
Change to netincome - - - 0.27M 0.39M
Capital expenditures 0.00M 0.00M 0.06M 0.00M 0.03M
Change in working capital 0.01M 1.32M 0.81M 0.06M 0.00M
Stock based compensation - - 0.28M - -
Other non cash items 0.23M -4.26M -1.04M - 6.14M
Free cash flow -4.44M -2.94M -5.32M -5.13M -6.16M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
1AD
Adalta Ltd		 -
-%		 0.00 - - 15.89 17.36 5.50 -1.06
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Adalta Ltd

AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.

117 Camberwell Road, Hawthorn East, VIC, Australia, 3123

61 3 9479 5159

https://www.adalta.com.au

2

Name Title Year Born
Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D. CEO, MD & Director NA
Mr. Cameron Jones C.A. Company Sec. NA
Mr. Angus Tester Ph.D. Senior Director of Operations NA
Ms. Janette Dixon Head of Business Development NA
Mr. Cameron Jones C.A. Company Secretary NA
Mr. Angus Tester Ph.D. Senior Director of Operations NA
Ms. Janette Dixon Head of Business Development NA
Mr. Cameron Jones C.A. Company Secretary NA
Mr. Angus Tester Ph.D. Senior Director of Operations NA
Ms. Janette Dixon Head of Business Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…